In short
Clinical trials are investigating Vib1116 in people with Sjögren’s syndrome. This article explains what the study aimed to evaluate, including safety and effectiveness, and which patients were included, such as those with systemic disease activity or ongoing symptoms.
Key points
- Clinical trials investigating Vib1116 focused on Sjögren’s syndrome. The main study was a Phase 2 trial in 312 participants and was completed. It looked at both people with moderate-to-severe systemic disease activity and people with an unsatisfactory symptom state. The trial measured changes in ESSDAI and ESSPRI scores, which show disease activity and patient-reported symptoms. Overall, the research aimed to learn whether Vib1116 could help with both body-wide disease features and daily symptoms.
Trial overview
The main clinical trial for Vib1116 was a Phase 2 study in people with Sjögren’s syndrome. It was an interventional study, which means participants received a study treatment or a control treatment so researchers could compare outcomes. The trial was completed and enrolled 312 participants.
Who was studied
The study focused on participants with Sjögren’s syndrome. The brief summary shows two groups of interest: people with moderate-to-severe systemic disease activity and people with an unsatisfactory symptom state. In simple terms, this means the trial looked at people whose disease was affecting the body in a more serious way, or whose symptoms were still not well controlled.
What the trial measured
The main outcomes were changes from baseline in two scores: the ESSDAI total score and the ESSPRI total score. ESSDAI measures disease activity, meaning how active the illness is in the body. ESSPRI measures patient-reported symptoms, meaning how patients themselves rate their symptoms. The trial planned to compare these scores at Week XX, as listed in the source data.
Trial phase and status
This study was in Phase 2. Phase 2 trials usually look more closely at whether a treatment may help and continue to monitor safety. The study status was Completed.
Treatment groups
The intervention list shows Vib1116 given by subcutaneous use, which means under the skin. The source also lists commercially available 0.9% saline solution intended for subcutaneous administration as a comparison treatment. The trial data do not provide more detail on the group assignments in the source text, so the main point is that the study compared Vib1116 with a saline control in this research setting.
What the results were designed to show
The study was designed to see whether Vib1116 could improve the body-wide features of Sjögren’s syndrome and the symptoms that patients feel in daily life. By measuring both ESSDAI and ESSPRI, the researchers aimed to capture both clinical disease activity and the patient’s own experience of the illness. This makes the trial important for understanding whether the treatment may help in more than one way for people with Sjögren’s syndrome.